IL-22BP mRNA vaccine injection
2024-1911
Phase 1 mab active
Quick answer
IL-22BP mRNA vaccine injection for Refractory Malignant Solid Tumors is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Refractory Malignant Solid Tumors
- Phase
- Phase 1
- Modality
- mab
- Status
- active